Targeting the extradomain A of fibronectin allows identification of vascular resistance to antiangiogenic therapy in experimental glioma.

about

Targeting the extradomain A of fibronectin allows identification of vascular resistance to antiangiogenic therapy in experimental glioma.

Item

http://www.wikidata.org/entity/Q55362761

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Targeting the extradomain A of ...... herapy in experimental glioma.

@en

Targeting the extradomain A of ...... herapy in experimental glioma.

@nl

type

Item

label

Targeting the extradomain A of ...... herapy in experimental glioma.

@en

Targeting the extradomain A of ...... herapy in experimental glioma.

@nl

prefLabel

Targeting the extradomain A of ...... herapy in experimental glioma.

@en

Targeting the extradomain A of ...... herapy in experimental glioma.

@nl

P1476

Targeting the extradomain A of ...... herapy in experimental glioma.

@en

P2093

Alessandro Palumbo

http://www.w3.org/2001/XMLSchema#string

Anna Lena Datwyler

http://www.w3.org/2001/XMLSchema#string

Christoph Harms

http://www.w3.org/2001/XMLSchema#string

Dario Neri

http://www.w3.org/2001/XMLSchema#string

Eveline Trachsel

http://www.w3.org/2001/XMLSchema#string

Gilla Lättig-Tünnemann

http://www.w3.org/2001/XMLSchema#string

Güliz Acker

http://www.w3.org/2001/XMLSchema#string

Irina Kremenetskaia

http://www.w3.org/2001/XMLSchema#string

Jan Klohs

http://www.w3.org/2001/XMLSchema#string

Janet Lips

http://www.w3.org/2001/XMLSchema#string

P2860

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

Current status and future directions of anti-angiogenic therapy for gliomas

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.

Antibody-drug conjugates: basic concepts, examples and future perspectives.

Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors.

Molecular classification of gliomas.

Antiangiogenic therapy inhibits the recruitment of vascular accessory cells to the perivascular niche in glioma angiogenesis.

Microvascular biodistribution of L19-SIP in angiogenesis targeting strategies.

Effects of sunitinib on tumor hemodynamics and delivery of chemotherapy.

P304

27760-27772

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.25570

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-06-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29963235

http://www.w3.org/2001/XMLSchema#string

P932

6021244

http://www.w3.org/2001/XMLSchema#string